Reduction of Orc6 expression sensitizes human colon cancer cells to 5-fluorouracil and cisplatin

PLoS ONE

Volumn 3, Issue 12, 2008, Pages

  Gavin, Elaine J ^a   Song, Bo ^b   Wang, Yuan ^b   Xi, Yaguang ^a   Ju, Jingfang ^a,b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b STONY BROOK UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; ORIGIN RECOGNITION COMPLEX; PROTEIN ORC6; PROTEIN P21; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; CYCLIN DEPENDENT KINASE INHIBITOR 1B; STRESS ACTIVATED PROTEIN KINASE 1; TP53 PROTEIN, HUMAN;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HCT116; CHEMOSENSITIVITY; COLON CANCER; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOWN REGULATION; HUMAN; HUMAN CELL; MULTINUCLEAR CELL; NULL CELL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; WESTERN BLOTTING; WILD TYPE; BIOSYNTHESIS; CELL NUCLEUS; COLON TUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; TUMOR CELL LINE; TUMOR SUPPRESSOR GENE;

CELL LINE, TUMOR; CELL NUCLEUS; CISPLATIN; COLONIC NEOPLASMS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; FLUOROURACIL; G1 PHASE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 8; ORIGIN RECOGNITION COMPLEX; PHOSPHORYLATION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 58149191247     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0004054     Document Type: Article

References (24)

1. Chesnokov IN, Chesnokova ON, Botchan M (2003) A cytokinetic function of Drosophila ORC6 protein resides in a domain distinct from its replication activity. Proc Natl Acad Sci U S A 100: 9150-9155.
2. Balasov M, Huijbregts RP, Chesnokov I (2007) Role of the Orc6 protein in origin recognition complex-dependent DNA binding and replication in Drosophila melanogaster. Mol Cell Biol 27: 3143-3153.
3. Chen S, de Vries MA, Bell SP (2007) Orc6 is required for dynamic recruitment of Cdt1 during repeated Mcm2-7 loading. Genes Dev 21: 2897-2907.
4. Li JJ, Herskowitz I (1993) Isolation of ORC6, a component of the yeast origin recognition complex by a one-hybrid system. Science 262: 1870-1874.
5. Semple JW, Da-Silva LF, Jervis EJ, Ah-Kee J, Al-Attar H, et al. (2006) An essential role for Orc6 in DNA replication through maintenance of pre-replicative complexes. EMBO J 25: 5150-5158.
6. Wilmes GM, Archambault V, Austin RJ, Jacobson MD, Bell SP, et al. (2004) Interaction of the S-phase cyclin Clb5 with an "RXL" docking sequence in the initiator protein Orc6 provides an origin-localized replication control switch. Genes Dev 18: 981-991.
7. Jin S, Tong T, Fan W, Fan F, Antinore MJ, et al. (2002) GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene 21: 8696-8704.
8. Prasanth SG, Prasanth KV, Stillman B (2002) Orc6 involved in DNA replication, chromosome segregation, and cytokinesis. Science 297: 1026-1031.
9. Siddiqui K, Stillman B (2007) ATP-dependent assembly of the human origin recognition complex. J Biol Chem 282: 32370-32383.
10. Xi Y, Nakajima G, Schmitz JC, Chu E, Ju J (2006) Multi-level gene expression profiles affected by thymidylate synthase and 5-fluorouracil in colon cancer. BMC Genomics 7: 68.
11. Xi Y, Formentini A, Nakajima G, Kornmann M, Ju J (2008) Validation of biomarkers associated with 5-fluorouracil and thymidylate synthase in colorectal cancer. Oncol Rep 19: 257-262.
12. Baker SJ, Markowitz S, Fearon ER, Willson JK, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
13. Baker SJ, Preisinger AC, Jessup JM, Paraskeva C, Markowitz S, et al. (1990) p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50: 7717-7722.
14. Wang XW, Zhan Q, Coursen JD, Khan MA, Kontny HU, et al. (1999) GADD45 induction of a G2/M cell cycle checkpoint. Proc Natl Acad Sci U S A 96: 3706-3711.
15. Yang J, Zhu H, Murphy TL, Ouyang W, Murphy KM (2001) IL-18-stimulated GADD45 beta required in cytokine-induced, but not TCR-induced, IFN-gamma production. Nat Immunol 2: 157-164.
16. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, et al. (1994) Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 266: 1376-1380.
17. Vairapandi M, Azam N, Balliet AG, Hoffman B, Liebermann DA (2000) Characterization of MyD118, Gadd45, and proliferating cell nuclear antigen (PCNA) interacting domains. PCNA impedes MyD118 AND Gadd45-mediated negative growth control. J Biol Chem 275: 16810-16819.
18. Azam N, Vairapandi M, Zhang W, Hoffman B, Liebermann DA (2001) Interaction of CR6 (GADD45gamma ) with proliferating cell nuclear antigen impedes negative growth control. J Biol Chem 276: 2766-2774.
19. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ (2002) Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts. Nat Genet 32: 201-205.
20. Deng Y, Ren X, Yang L, Lin Y, Wu X (2003) A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 115: 61-70.
21. Lamb JA, Ventura JJ, Hess P, Flavell RA, Davis RJ (2003) JunD mediates survival signaling by the JNK signal transduction pathway. Mol Cell 11: 1479-1489.
22. Wada T, Nakagawa K, Watanabe T, Nishitai G, Seo J, et al. (2001) Impaired synergistic activation of stress-activated protein kinase SAPK/ JNK in mouse embryonic stem cells lacking SEK1/MKK4: different contribution of SEK2/MKK7 isoforms to the synergistic activation. J Biol Chem 276: 30892-30897.
23. Mani A, Gelmann EP (2005) The ubiquitin-proteasome pathway and its role in cancer. J Clin Oncol 23: 4776-4789.
24. Chen Z, Speck C, Wendel P, Tang C, Stillman B, et al. (2008) The architecture of the DNA replication origin recognition complex in Saccharomyces cerevisiae. Proc Natl Acad Sci U S A 105: 10326-10331.